Swedish Biomimetics 3000® is focused on commercialising an innovative, biomimetically inspired, pharmaceutical manufacturing technology, which enables the continuous production of various high value therapeutic oligomers (peptides and oligonucleotides). Peptides are of particular interest in the pharmaceutical industry for targeting disease given their high target specificity, high potency and their biodegradation to amino acids in the body. To date, two major barriers have impeded their adoption: high costs of production and route of administration. Significant improvements in the latter has reignited interest in peptides, however the challenge of high cost of production remains unanswered.
Swedish Biomimetics 3000’s® technology – called Microlot (µLOT® ) is the first major disruption in therapeutic peptide manufacturing in the past 50 years. To date, therapeutic peptides have been manufactured in batch, which aside from reported high costs for pharmaceutical companies and health services/end-users, may also result in promising drugs being abandoned and approved drugs not reaching middle or low income markets. Batch production can also introduce risk of variable quality, long development times and supply volatility. µLOT’s® continuous production addresses all of these problems.
Swedish Biomimetics 3000’s® vision is to commercially exploit the µLOT® IP Platform Technology:
(a) By: Working in partnership with pharmaceutical companies specialized in peptides and oligonucleotides by out-licensing the µLOT® IP Technology to those companies who have strategically elected to manufacture their products in-house.
(b) By: Addressing the specialist service manufacturing market for peptides and oligonucleotides by entering into a joint venture collaboration with established CMO’s and or CDMO’s.